Advances of Krüppel-like factors in hepatocellular carcinoma

Abstract

Zhao Chuanxi, Zhu Tingting, Liu Mingguo, Cao Lili. Advances of Krüppel-like factors in hepatocellular carcinoma[J]. Journal of International Oncology, 2020, 47(2): 119-122.

References30

[1]	McConnell BB, Yang VW . Mammalian Krüppel-like factors in health and diseases[J]. Physiol Rev, 2010,90(4):1337-1381. DOI: 10.1152/physrev.00058.2009.
[2]	Huang Y, Ren Q . A Krüppel-like factor from Macrobrachium rosenbergii (MrKLF) involved in innate immunity against pathogen infection[J]. Fish Shellfish Immunol, 2019,95:519-527. DOI: 10.1016/j.fsi.2019.10.070.
[3]	Lu XJ, Shi Y, Chen JL , et al. Krüppel-like factors in hepatocellular carcinoma[J]. Tumour Biol, 2015,36(2):533-541. DOI: 10.1007/s13277-015-3127-6.
[4]	Yin X, Li YW, Jin JJ , et al. The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma[J]. Oncol Lett, 2013,5(4):1155-1162. DOI: 10.3892/ol.2013.1151.
[5]	Tian C, Yao S, Liu L , et al. Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma[J]. Int J Mol Med, 2017,39(1):47-56. DOI: 10.3892/ijmm.2016.2812.
[6]	Dong X, Wang F, Xue Y , et al. MicroRNA-9-5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway[J]. Int J Mol Med, 2019,43(3):1417-1429. DOI: 10.3892/ijmm.2019.4062.
[7]	Li Q, Song W, Wang W , et al. Suppression of epithelial-mesenchymal transition in hepatocellular carcinoma cells by Krüppel-like factor 4[J]. Oncotarget, 2016,7(20):29749-29760. DOI: 10.18632/oncotarget.8831.
[8]	Sun H, Peng Z, Tang H , et al. Loss of KLF4 and consequential downregulation of Smad7 exacerbate oncogenic TGF-β signaling in and promote progression of hepatocellular carcinoma[J]. Oncogene, 2017,36(21):2957-2968. DOI: 10.1038/onc.2016.447.
[9]	Sung MT, Hsu HT, Lee CC , et al. Krüppel-like factor 4 modulates the migration and invasion of hepatoma cells by suppressing TIMP-1 and TIMP-2[J]. Oncol Rep, 2015,34(1):439-446. DOI: 10.3892/or.2015.3964.
[10]	Sun H, Tang H, Xie D , et al. Krüppel-like factor 4 blocks hepatocellular carcinoma dedifferentiation and progression through activation of hepatocyte nuclear factor-6[J]. Clin Cancer Res, 2016,22(2):502-512. DOI: 10.1158/1078-0432.ccr-15-0528.
[11]	Wen PH, Wang DY, Zhang JK , et al. Krüppel-like factor 6 suppresses growth and invasion of hepatocellular carcinoma cells in vitro and in vivo[J]. Int J Immunopathol Pharmacol, 2016,29(4):666-675. DOI: 10.1177/0394632016655171.
[12]	Muñoz Ú, Puche JE, Hannivoort R , et al. Hepatocyte growth factor enhances alternative splicing of the Krüppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1[J]. Mol Cancer Res, 2012,10(9):1216-1227. DOI: 10.1158/1541-7786.MCR-12-0213.
[13]	Zhenzhen Z, De'an T, Limin X , et al. New candidate tumor-suppressor gene KLF6 and its splice variant KLF6 SV2 counterbalancing expression in primary hepatocarcinoma[J]. Hepatogastroenterology, 2012,59(114):473-476. DOI: 10.5754/hge11283.
[14]	Hanoun N, Bureau C, Diab T , et al. The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions[J]. J Hepatol, 2010,53(5):880-888. DOI: 10.1016/j.jhep.2010.04.038.
[15]	Sirach E, Bureau C, Péron JM , et al. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis[J]. Cell Death Differ, 2007,14(6):1202-1210. DOI: 10.1038/sj.cdd.4402114.
[16]	Bureau C, Péron JM, Bouisson M , et al. Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2008,23(1):78-86. DOI: 10.1111/j.1440-1746.2007.05234.x.
[17]	Lu XJ, Shi Y, Chen JL , et al. Krüppel-like factors in hepatocellular carcinoma[J]. Tumour Biol, 2015,36(2):533-541. DOI: 10.1007/s13277-015-3127-6. doi:10.1007/s13277-015-3127-6
[18]	Ahronian LG, Zhu LJ, Chen YW , et al. A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination[J]. Oncogene, 2016,35(35):4653-4662. DOI: 10.1038/onc.2016.2.
[19]	Fu DZ, Cheng Y, He H , et al. The fate of Krüppel-like factor 9-positive hepatic carcinoma cells may be determined by the programmed cell death protein 5[J]. Int J Oncol, 2014,44(1):153-160. DOI: 10.3892/ijo.2013.2147.
[20]	Sun J, Wang B, Liu Y , et al. Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression[J]. Cancer Lett, 2014,355(1):25-33. DOI: 10.1016/j.canlet.2014.09.022.
[21]	Wang YG, Liu J, Shi M , et al. LncRNA DGCR5 represses the development of hepatocellular carcinoma by targeting the miR-346/KLF14 axis[J]. J Cell Physiol, 2018,234(1):572-580. DOI: 10.1002/jcp.26779.
[22]	Liu FY, Deng YL, Li Y , et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma[J]. Med Oncol, 2013,30(1):425. DOI: 10.1007/s12032-012-0425-3.
[23]	An T, Dong T, Zhou H , et al. The transcription factor Krüppel-like factor 5 promotes cell growth and metastasis via activating PI3K/AKT/Snail signaling in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2019,508(1):159-168. DOI: 10.1016/j.bbrc.2018.11.084.
[24]	Maehara O, Sato F, Natsuizaka M , et al. A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma[J]. Cancer Biol Ther, 2015,16(10):1453-1461. DOI: 10.1080/15384047.2015.1070992.
[25]	Li JC, Yang XR, Sun HX , et al. Up-regulation of Krüppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma[J]. Gastroenterology, 2010,139(6):2146-2157, e12. DOI: 10.1053/j.gastro.2010.08.004.
[26]	Yang T, Cai SY, Zhang J , et al. Krüppel-like factor 8 is a new Wnt/beta-catenin signaling target gene and regulator in hepatocellular carcinoma[J]. PLoS One, 2012,7(6):e39668. DOI: 10.1371/journal.pone.0039668.
[27]	Shen YN, He HG, Shi Y , et al. Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/beta-catenin signaling[J]. Mol Carcinog, 2017,56(2):751-760. DOI: 10.1002/mc.22532.
[28]	Heo SH, Jeong ES, Lee KS , et al. Krüppel-like factor 10 null mice exhibit lower tumor incidence and suppressed cellular proliferation activity following chemically induced liver tumorigenesis[J]. Oncol Rep, 2015,33(4):2037-2044. DOI: 10.3892/or.2015.3801.
[29]	Zou K, Lu X, Ye K , et al. Krüppel-like factor 2 promotes cell proliferation in hepatocellular carcinoma through up-regulation of c-myc[J]. Cancer Biol Ther, 2016,17(1):20-26. DOI: 10.1080/15384047.2015.1108484.
[30]	Lin J, Tan H, Nie Y , et al. Krüppel-like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway[J]. Cancer Sci, 2019,110(4):1220-1231. DOI: 10.1111/cas.13961.

Advances of Krüppel-like factors in hepatocellular carcinoma

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References30

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[5]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu.Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells[J]. Journal of International Oncology, 2023, 50(7): 413-418.
[6]	Li Jiaxuan, Feng Yinglu.Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.
[7]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke.Diagnostic value of serum TIM-3 in patients with liver cancer[J]. Journal of International Oncology, 2022, 49(9): 537-542.
[8]	Zhang Yumin, Zhao Xianwei, He Qianjin, Chen Jieneng.Value of contrast-enhanced ultrasound combined with serum CXCL8 and CXCR2 in the evaluation of postoperative efficacy of transcatheter arterial chemoembolization for primary liver cancer[J]. Journal of International Oncology, 2022, 49(10): 592-596.
[9]	Di Weihua, Zhao Xuemei.Research progress on the relationship between DNA damage repair genes and liver cancer[J]. Journal of International Oncology, 2022, 49(10): 635-638.
[10]	Du Jiahang, Chen Dong, Chen Yaoting.Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2021, 48(9): 572-.
[11]	Han Baojun.Expression of histone acetyltransferase P300 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of International Oncology, 2021, 48(7): 415-419.
[12]	Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang.Progress of biomarkers in liver cancer[J]. Journal of International Oncology, 2021, 48(4): 241-245.
[13]	Xiong Lin, Zhang Xiuyun, Zhang Xiaoyu, Li Yue, Xu Ximing.IWR-1-endo affects the migration and proliferation of hepatocarcinoma cells by inhibiting the Wnt pathway[J]. Journal of International Oncology, 2021, 48(12): 711-715.
[14]	Liu Junguo, Zhang Jinjuan, Wang Yijun.Clinical application progress of variations in the technique of liver partition from ALPPS[J]. Journal of International Oncology, 2020, 47(8): 492-495.
[15]	Xin Ruiqiang, Song Xiaoping, Zhang Fan, Sun Ying, Wang Tao, Sun Wei.Mechanism of SUMO regulating XBP1 mediated endoplasmic reticulum stress on the progression of liver cancer[J]. Journal of International Oncology, 2020, 47(7): 397-403.